Skip to content

Evaluation and clinical research of bioactive materials that inhibit tumor recurrence

Evaluation and clinical research of bioactive materials that inhibit tumor recurrence

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300077268
Enrollment
Unknown
Registered
2023-11-02
Start date
2023-11-05
Completion date
Unknown
Last updated
2023-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

It is suitable for filling and stabilizing the surgical defect site of bone tumor

Interventions

Sponsors

Beijing Jishuitan Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Subject and/or guardian willing and able to sign informed consent. 2. Age 18-80 years old (inclusive), gender is not limited. 3. Patients who meet the indications for cement filling surgery. 4. Good compliance, willing to follow doctor's advice and able to follow up and observe as required.

Exclusion criteria

Exclusion criteria: 1. Those whose tumors compress peripheral nerves or spinal cord and have clear symptoms and signs of nerve damage. 2. The presence of active foci of infection throughout the body. 3. History of previous cement filling surgery at the lesion site to be treated. 4. The number of lesions requiring cement filling surgery at the same time= 3. 5. Those who are allergic to the composition of bone cement. 6. Severe cardiopulmonary insufficiency or other chronic diseases can not tolerate surgery. 7. Those with coagulation dysfunction and bleeding tendency. 8. Pregnant or lactating women. 9. Patients who are mentally incompetent or unable to understand the requirements to participate in the study. 10. Poor compliance, unwillingness or inability to follow instructions in postoperative therapy and/or rehabilitation protocols. 11. Patients enrolled in other clinical studies within 3 months prior to the start of this study. 12. Patients deemed unsuitable for enrollment by the investigator.

Design outcomes

Primary

MeasureTime frame
The effective rate of VAS pain relief 3 days ± 1 day after operation;

Secondary

MeasureTime frame
Efficacy rate of VAS pain relief (1 month postoperative, 3 months postoperative, 6 months postoperative, 12 months postoperative);Tumor recurrence rate at 6 and 12 months after surgery;

Countries

China

Contacts

Public ContactXiaohui Niu

Beijing Jishuitan Hospital; Beijing accumulates puddle hospital

niuxiaohui@263.net+86 138 0113 2522

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026